Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | ITK | Q08881 | 2/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209183 | 0.87 | CYP11B1 (0.49) | AXLCDK8TNIKGSK3BALOX5AP | |
| SCHEMBL8320264 | 0.80 | AXL (0.52) | AXLCDK8TNIKGSK3BKIT | |
| SCHEMBL8323580 | 0.75 | AXL (0.55) | AXLCDK8TNIKKITNTRK1 | |
| SCHEMBL8320927 | 0.74 | AXL (0.73) | AXLCDK8TNIKGSK3BKIT | |
| SCHEMBL12764154 | 0.74 | CDK8 (0.56) | AXLCDK8TNIKGSK3BAAK1 | |
| SCHEMBL8320981 | 0.73 | CDK8 (0.73) | AXLCDK8TNIKKITNTRK1 | |
| SCHEMBL13975665 | 0.73 | CHUK (0.41) | — | |
| SCHEMBL8323599 | 0.73 | CDK8 (0.52) | AXLCDK8TNIKKIT | |
| SCHEMBL8320561 | 0.73 | CDK8 (0.49) | AXLCDK8TNIKKITNTRK1 | |
| SCHEMBL12764151 | 0.72 | CDK8 (0.57) | AXLCDK8TNIKGSK3BAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | UNIVERSITY OF MASSACHUSETTS | 2015-11-05 | — | — | US | disclosed |
| US-7897572-B1 | Theraputic methods for type I diabetes | UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL (US) | 2011-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313881-A1 | Therapeutic Methods for Type I Diabetes | MAPK9, IAPP, RNASE1 | AXL 2467/4885CDK8 1731/4885TNIK 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.